RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...